These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30146960)

  • 41. Overcoming the current deadlock in antibiotic research.
    Schäberle TF; Hack IM
    Trends Microbiol; 2014 Apr; 22(4):165-7. PubMed ID: 24698433
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reimbursement under DRGs: implementation in New Jersey.
    Davies RH; Westfall G
    Health Serv Res; 1983; 18(2 Pt 1):233-47. PubMed ID: 6409841
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Meeting the societal need for new antibiotics: the challenges for the pharmaceutical industry.
    O'Brien S
    Br J Clin Pharmacol; 2015 Feb; 79(2):168-72. PubMed ID: 25601037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New business models for antibiotic innovation.
    So AD; Shah TA
    Ups J Med Sci; 2014 May; 119(2):176-80. PubMed ID: 24646116
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A qualitative assessment of the Medicare prospective payment system.
    Broyles RW; Rosko MD
    Soc Sci Med; 1985; 20(11):1185-90. PubMed ID: 3927487
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DRGs, incentives, hospitals, and physicians.
    Berki SE
    Health Aff (Millwood); 1985; 4(4):70-6. PubMed ID: 3938445
    [No Abstract]   [Full Text] [Related]  

  • 47. Early market access for unauthorized drugs in Italy: The value-based price for reimbursement decisions.
    Maratea D; Venturini F
    Eur J Intern Med; 2016 May; 30():e15-e16. PubMed ID: 26851984
    [No Abstract]   [Full Text] [Related]  

  • 48. Pricing of pharmaceuticals. Assessing the pricing potential by a pricing matrix model.
    Nuijten MJ; Kosa J
    Eur J Health Econ; 2004 Jun; 5(2):110-5. PubMed ID: 15452745
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Teixobactins: a new class of 21st century antibiotics to combat multidrug-resistant bacterial pathogens.
    Iyer A; Madder A; Singh I
    Future Microbiol; 2019 Apr; 14():457-460. PubMed ID: 31033354
    [No Abstract]   [Full Text] [Related]  

  • 50. Antibiotics: the changing regulatory and pharmaceutical industry paradigm.
    Bax R; Green S
    J Antimicrob Chemother; 2015 May; 70(5):1281-4. PubMed ID: 25634991
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluating outpatient versus inpatient costs in endophthalmitis management.
    Sulkes DJ; Scott IU; Flynn HW; Feuer WJ
    Retina; 2002 Dec; 22(6):747-51. PubMed ID: 12476101
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The economics of hospital reimbursement.
    Hornbrook M; Rafferty J
    Adv Health Econ Health Serv Res; 1982; 3():79-115. PubMed ID: 10309786
    [No Abstract]   [Full Text] [Related]  

  • 53. Evaluating financial viability of clinical programs under prospective pricing.
    Barnard C
    QRB Qual Rev Bull; 1985 Mar; 11(3):81-6. PubMed ID: 3921893
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Encouraging Sustainable Use of Antibiotics: A Commentary on the DRIVE-AB Recommended Innovation Incentives.
    Morel CM; Edwards SE
    J Law Med Ethics; 2018 Jun; 46(1_suppl):75-80. PubMed ID: 30146962
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of diagnosis related groups and prospective pricing systems on health care management.
    Crawford M; Fottler MD
    Health Care Manage Rev; 1985; 10(4):73-84. PubMed ID: 3932257
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lack of funding could undermine UK antibiotic resistance strategy, say experts.
    O'Dowd A
    BMJ; 2013 Dec; 347():f7618. PubMed ID: 24355390
    [No Abstract]   [Full Text] [Related]  

  • 57. Antibiotic resistance as a major public health concern: epidemiology and economic impact.
    Ciorba V; Odone A; Veronesi L; Pasquarella C; Signorelli C
    Ann Ig; 2015; 27(3):562-79. PubMed ID: 26152543
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [From the discovery of antibiotics to emerging highly drug-resistant bacteria].
    Meunier O
    Soins; 2015; (797):14-20. PubMed ID: 26154354
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulatory Incentives for Antibiotic Drug Development: A Review of Recent Proposals.
    Sinha MS; Kesselheim AS
    Bioorg Med Chem; 2016 Dec; 24(24):6446-6451. PubMed ID: 27591793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improving antibiotic markets for long-term sustainability.
    Kesselheim AS; Outterson K
    Yale J Health Policy Law Ethics; 2011; 11(1):101-67. PubMed ID: 21381513
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.